Research Article
Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B
Table 5
Clinical, epidemiologic, and histological characteristics of all ETV-resistant group patients (2).
| | No. | Baseline | Period to switch (months) | Rescue antiviral treatment | At switch | ALT < 30 U/L after switch (weeks) | HBV DNA < 3 LogC/mL after switch (weeks) | | ALT (U/L) | HBV DNA (LogC/mL) | HBcrAg (LogU/mL) | ALT (U/L) | HBV DNA (LogC/mL) | HBcrAg (LogU/mL) |
| | 1 | 32 | 2.9 | 5.7 | 121 | ETV + TDF | 42 | 5.7 | — | 97 | 12 | | 2 | 20 | 4.1 | 3 | 33 | LAM + ADV | 19 | 2.6 | — | — | — | | 3 | 592 | 5.4 | 6.1 | 33 | TDF | 18 | 2.1 | — | — | — | | 4 | 116 | 7.1 | 6 | 77 | ETV + TDF | 19 | 4.2 | 3 | — | 8 | | 5 | 213 | 9 | — | 2 | ETV + TDF | 1144 | 8.1 | — | 46 | 20 | | 6 | 22 | 5.9 | — | 70 | ETV + TDF | 19 | 1.7 | 2.9 | — | — | | 7 | 95 | 8.9 | 6.8 | 42 | ETV + TAF | 25 | 6.9 | 7 | — | 24 | | 8 | 161 | 8.9 | 6.8 | 92 | TAF | 33 | 1.7 | 5.5 | 28 | — | | 9 | 97 | 4.9 | 4.2 | 137 | TAF | 18 | 1.7 | 2.9 | — | — | | 10 | 34 | 8.8 | 6.8 | 38 | TAF | 18 | 2.8 | 7 | — | — | | 11 | 189 | 9.4 | 6.8 | 115 | TAF | 20 | 1.7 | 4.1 | — | — | | 12 | 34 | 7.7 | 6.8 | 64 | TAF | 10 | 1.7 | 4.9 | — | — | | 13 | 108 | 8.9 | 6.8 | 84 | TAF | 20 | 1.7 | 5.7 | — | — | | 14 | 88 | 6.9 | 6.8 | 117 | TAF | 28 | 1.7 | 4 | — | — | | 15 | 90 | 7.6 | 6.8 | 69 | TAF | 45 | 1.7 | 5.7 | 33 | — |
|
|
